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Abstract
Background: The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and
BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be
substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers.
Further, previous studies have not considered the effect of RRSO in the context of natural menopause.
Methods: A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed
for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was
modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and
postmenopausal women.
Results: There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94–1.61)
or BRCA2 (HR = 0.88; 95% CI 0.62–1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI
0.40–1.15) and 1.07 (95% CI 0.69–1.64) for RRSO carried out before or after age 45 years, respectively. The HR
for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26–0.99 for
5 years or longer after RRSO). Estimates for premenopausal women were similar.
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Conclusion: We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A
potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO.
These results may inform counselling and management of carriers with respect to RRSO.
Keywords: Breast cancer, BRCA1, BRCA2, Mutation, Risk-reducing salpingo-oophorectomy
Background
Women carrying germline mutations in BRCA1 or BRCA2
are at high risk of developing breast cancer and ovarian
cancer [1, 2]. Mutation carriers undergo enhanced cancer
surveillance and may be offered interventions including
risk-reducing mastectomy (RRM) or risk-reducing
salpingo-oophorectomy (RRSO). While RRSO substan-
tially reduces the risk of developing ovarian cancer, its ef-
fect on breast cancer risk is uncertain. Some studies have
reported substantial breast cancer risk reduction of up to
50% following RRSO [3–6]. However, these studies may
have been subject to bias and confounding [7, 8]. Biases
include ‘cancer-induced testing bias’, which can occur if
mutation testing is conducted as a result of a breast cancer
diagnosis and follow-up before DNA testing is included in
the analysis, and ‘immortal person-time bias’, caused by
excluding follow-up prior to RRSO uptake. Heemskerk-
Gerritsen et al. found no evidence for an association be-
tween RRSO and breast cancer after eliminating several
sources of bias [9, 10]. Prospective cohort studies can
avoid such biases, but large studies with long follow-up
are required to provide sufficient power.
Here, we report results from a large international
collaborative, multi-centre, prospective cohort of 2272
BRCA1 and 1605 BRCA2 mutation carriers. We exam-
ined the association between RRSO and breast cancer
risk according to the timing of RRSO relative to meno-
pause and time since RRSO.
Methods
Study design and study population
We combined information from three consortia: The
International BRCA1/2 Carrier Cohort Study (IBCCS),
Kathleen Cuningham Foundation Consortium for Re-
search Into Familial Breast Cancer (kConFab) Follow-Up
Study, and Breast Cancer Family Registry (BCFR) (Tables 1
and 2, Additional file 1: Table S1) [11–15]. In total, 9856
BRCA1/2 mutation carriers were included. Eighty-nine
percent of participants were invited into the studies after
receiving their clinical genetic test results, while 3% were
recruited as an untested member of a mutation-carrying
family and opted for a clinical test only after enrolment.
Seven percent were tested in a research setting, and it was
unknown whether or when they opted for a clinical test.
Sixty-six percent of participants were enrolled through
one of five ongoing nationwide studies in the UK and
Ireland (Epidemiological Study of Familial Breast Cancer
[EMBRACE]), France (Gene Etude Prospective Sein
Ovaire [GENEPSO]), Netherlands (Hereditary Breast and
Ovarian cancer study Netherlands [HEBON]), Australia
and New Zealand (kConFab), and Austria (Medical Uni-
versity of Vienna [MUV]). Other studies were centre-
based.
Study participants
Women were eligible if they were 18–80 years of age at
recruitment and tested positive for a pathogenic BRCA1
Table 1 Prospective cohort of BRCA1 and BRCA2 mutation carriers
IBCCS studies BRCA1 mutation carriers BRCA2 mutation carriers
Number of
women
FUP time mean,
years (sd)
BC, N Mean age BC
diagnosis, years
Number of
women
FUP time mean,
years (sd)
BC, N Mean age BC
diagnosis, years
EMBRACE 471 4.4 (3.0) 41 45.4 478 3.9 (2.5) 42 48.2
GENEPSO 486 3.6 (2.4) 46 45.8 325 3.2 (1.9) 18 48.8
HEBON 242 7.2 (3.6) 40 47.6 75 5.9 (2.8) 4 47.3
kConFab 325 6.7 (3.8) 55 42.2 288 6.4 (3.7) 38 50.5
BCFR 327 7.7 (4.4) 50 47.1 255 7.5 (4.3) 33 49.8
Other studiesa 421 4.9 (3.2) 37 41.4 184 4.3 (2.9) 22 47.0
Total 2272 5.4 (3.7) 269 44.9 1605 4.9 (3.4) 157 49.0
BC breast cancer, FUP follow-up, sd standard deviation
aOther studies: MUV-Austria, INHERIT, OUH, GC-HBOC, NIO-Hungary, CNIO, HCSC, LUND-BRCA, STOCKHOLM-BRCA, IHCC, and MODSQUAD (see Additional file 1:
Table S1 for details)
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or BRCA2 mutation, had no cancer history, and had
retained both breasts at the date of genetic testing or study
enrolment, whichever was last (N = 3886). One woman
was excluded as she had been diagnosed with Turner syn-
drome and eight excluded as it was unclear whether they
had had a hysterectomy or RRSO before recruitment.
Data collection
Study participants were invited to complete a baseline ques-
tionnaire and a series of follow-up questionnaires. The ques-
tionnaires requested detailed information on known or
suspected risk factors for breast and ovarian cancer, includ-
ing family history, reproductive history, and surgical
Table 2 Characteristics of the cohort of BRCA1 and BRCA2 mutation carriers
BRCA1 mutation carriers BRCA2 mutation carriers
Unaffected women
(N = 2003)
Women with
breast cancer
(N = 269)
Unaffected women
(N = 1448)
Women with
breast cancer
(N = 157)
Total person-years of follow-up 11,207 1134 7286 600
Person-years of follow-up (mean (sd)) 5.60 (3.67) 4.21 (3.27) 5.03 (3.44) 3.82 (3.08)
Age at start of follow-up (mean (sd)) 37.51 (11.80) 40.68 (10.25) 40.00 (12.53) 45.14 (10.11)
Age at diagnosis/censoring (mean (sd)) 43.10 (12.28) 44.90 (10.33) 45.00 (13.00) 48.97 (10.30)
Reason for censoring
Breast cancer 0 269 0 157
Ovarian cancer 49 3a 9 1a
Other cancer 45 5a 28 2a
RRM 299 – 181 –
Death 5 – 8 –
Unaffected at last follow-up time 1605 – 1222 –
Year of birth
≤ 1960 604 (83.54) 119 (16.46) 500 (84.75) 90 (15.25)
> 1960 1399 (90.32) 150 (9.68) 948 (93.40) 67 (6.60)
Menopausal status
Premenopausal at censoringb
Last informationc after censoring 512 69 344 35
Last information before censoringd 585 58 473 35
Postmenopausal
Natural menopause age known 194 27 182 31
Natural menopause age unknown 5 0 7 1
Post-hysterectomy 70 12 64 11
Unknown menopausal status 62 13 33 8
RRSO status at censoring
No RRSO
Last information after censoring 664 110 467 79
Last information before censoring 618 44 535 27
RRSO 721 115 446 51
As reason for menopausee 574 90 345 36
After natural menopause 101 18 76 10
After hysterectomy 46 7 25 5
RRSO risk-reducing salpingo-oophorectomy, RRM risk-reducing mastectomy
aDiagnosed at the same time as breast cancer
bFifteen women did not report age at menopause but were older than 60 years at the end of follow-up
cInformation from questionnaire and record linkage
dAge last known to be premenopausal mean 32.3 years, median 31 years for BRCA1 mutation carriers: mean 33.9, median 34 years for BRCA2 mutation carriers.
Time between this age and end of censoring: mean 6.3, median 5 years for BRCA1 and mean 6 years, median 5 years for BRCA2 mutation carriers
eSeven women reported RRSO after age 60 years without first reporting natural menopause
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interventions including RRM or RRSO. The question-
naires also asked for information on age at last men-
struation, whether the woman had had any period in
the past year, the number of years/months since last
menstruation, and reason(s) for the stopping of pe-
riods. Age at menopause for those who indicated no
period in the past year was determined by adding 1 year to
‘age at last menstruation’. Women were considered pre-
menopausal if they indicated that they had had a period in
the past year, or if the ‘reason for periods stopping’ was
medication, oral contraceptive use, pregnancy, or breast-
feeding. Women reporting RRSO as the reason for meno-
pause were considered premenopausal until RRSO. After
hysterectomy, menopausal status was considered unknown.
In addition to questionnaires, some studies obtained
RRSO information from medical records or linkage to a
pathological registry. For the primary analysis, risk factor
information was updated from all available sources, in-
cluding post-diagnosis questionnaires and record link-
age. Occurrence of breast cancer was derived from data
from follow-up questionnaires and, for five studies,
through linkage to cancer registries. Information on vital
status was obtained from municipal or death registries,
medical records, or family members.
Distributions of dates of breast cancer diagnosis
and DNA testing are shown in Additional file 1:
Table S2.
Statistical analysis
We used Cox proportional hazards regression models to
assess the association with risk of breast cancer. Follow-up
started either at completion of baseline questionnaire or
mutation testing, whichever was latest. The primary end-
point was breast cancer (invasive or in situ). Follow-up
was censored at the earliest of RRM, diagnosis of breast
cancer, ovarian cancer or any other cancer, treatment with
chemotherapy or radiotherapy in the absence of informa-
tion about cancer, reaching age 80 years, or death. For
studies that used record linkage, follow-up was stopped at
the date on which record linkage was conducted or con-
sidered complete. For GENEPSO, there was no linkage to
cancer registries and women were censored at age at last
questionnaire. Women diagnosed with breast cancer
within 2 months of the start of follow-up were excluded
from all analyses. RRM occurring within 1 year of breast
cancer diagnosis were ignored. To investigate the associ-
ation of RRSO with breast cancer risk in premeno-
pausal women, women were also censored at natural
menopause, hysterectomy, or reaching age 60 years.
The association of RRSO with breast cancer risk after
natural menopause was investigated by starting follow-
up at the age of natural menopause. The association be-
tween age at natural menopause and breast cancer was
investigated by also censoring at RRSO. For hormone
replacement therapy (HRT) analyses, women were eli-
gible if they had never used HRT before baseline and
further censored at start of HRT.
A potential bias arises if completion of a subsequent
questionnaire is related to RRSO uptake or cancer diagno-
sis. In order to address this possibility, sensitivity analyses
were carried out in which RRSO status was changed at the
date of the questionnaire in which the information on
RRSO occurrence was reported, rather than the reported
age at RRSO (except for the HEBON study, for which
RRSO status was determined through record linkage). We
also carried out sensitivity analysis excluding women with
missing information on age or reason for menopause in
the baseline questionnaire, even if this information was
provided during follow-up (n = 514). Finally, we examined
the effect of excluding women with prevalent RRSO at the
start of follow-up (n = 403) (Additional file 1: Table S3).
Natural menopause and RRSO were coded as time-
dependent covariates in a Cox regression model. In
order to investigate the influence of age at RRSO on
breast cancer risk, analyses were carried out separately
for women experiencing RRSO before or after age 45
years. Analyses were also carried out estimating the haz-
ard ratio for developing breast cancer for different time
intervals following RRSO compared with no RRSO. The
trend in HR by time since RRSO was evaluated by cate-
gorising the time following RRSO as < 2 years, 2–5 years,
and > 5 years and fitting a time-varying parameter for
this ordinal covariate (coded 0, 1, 2). We conducted sep-
arate analyses for BRCA1 and BRCA2 mutation carriers.
We stratified for birth cohort and study (in six categor-
ies: EMBRACE, GENEPSO, HEBON, kConFab, BCFR,
and other studies (Table 1)) and used robust variance
estimation to account for familial clustering. We also
assessed associations by birth cohort (1920–1960 or
1961–1992) and study and adjusted for potential con-
founders including family history of breast cancer in
first- and second-degree relatives (collected either from
the baseline questionnaire or from pedigrees provided
by the genetics centres, and coded as unknown, none,
one, or two or more breast cancers), family history of
ovarian cancer (similarly defined), body mass index
(BMI) at baseline (derived from self-reported height and
weight), age at first birth (nulliparous, < 30 and ≥ 30),
parity (nulliparous, 1, 2 or 3, and ≥ 4 full-term pregnan-
cies), and HRT use (ever vs never, any formulation). The
distribution of potential confounders in study subjects is
shown in Additional file 1: Table S4. To test the hetero-
geneity between studies, fixed effect meta-analysis was
carried out. Statistical analyses were performed using
STATA v13 (StataCorp, College Station, TX). Statistical
tests were considered significant based on two-sided hy-
pothesis tests with p < 0.05.
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Results
Cohort characteristics
Among 2272 BRCA1 and 1605 BRCA2 mutation carriers
without a previous diagnosis of cancer or RRM, 269
BRCA1 and 157 BRCA2 mutation carriers were diagnosed
with breast cancer during follow-up (mean follow-up time
5.4 and 4.9 years for BRCA1 and BRCA2, respectively;
Tables 1 and 2). In total, 836 (37%) BRCA1 and 497 (31%)
BRCA2 mutation carriers reported RRSO, and 226 (10%)
BRCA1 and 221 (14%) BRCA2 mutation carriers went
through natural menopause, prior to censoring. Baseline
demographics of the cohort are shown in Table 2 and
Additional file 1: Table S4.
Association between RRSO and breast cancer risk
In the primary analysis, the hazard ratio (HR) for the
association between RRSO and breast cancer risk was
1.23 (95% CI 0.94–1.61) for BRCA1 and 0.88 (95% CI
0.62–1.24) for BRCA2 mutation carriers (Table 3). For
BRCA2 mutation carriers, the HR estimates were 0.68
(95% CI 0.40–1.15) and 1.07 (95% CI 0.69–1.64) for
RRSO carried out before and after age 45 years, respect-
ively. For BRCA1 mutation carriers, the estimated HRs
were close to 1 across varying times since RSSO (Table 3,
Fig. 1), while for BRCA2 mutation carriers, there was
some evidence that the HR decreased with increasing
time since RRSO (p-trend = 0.011) (Table 3). The HR
estimates of greater than 1.0 less than 2 years after RRSO
could reflect some inaccuracies in reporting the date of
surgery. A protective association was observed for BRCA2
mutation carriers 5 years after RRSO (HR= 0.51 (95% CI
0.26–0.99), p= 0.046, mean time between RRSO and end of
follow-up, 9.5 years) (Table 3), although there were differ-
ences across studies (p value for heterogeneity = 0.005)
(Fig. 2). The HR estimates were slightly lower for premeno-
pausal BRCA2 mutation carriers (Additional file 1: Table S5).
There was no significant association between RRSO and
breast cancer risk after natural menopause; however, only
221 BRCA1 and 213 BRCA2mutation carriers were included
in these analyses.
The results of the sensitivity analyses were broadly simi-
lar to the main analyses (Additional file 1: Tables S6-S8).
Analyses were also adjusted for potential confounders:
parity, BMI, age at first birth, and family history of breast
or ovarian cancer. Association between breast cancer risk
factors and uptake of RRSO are shown in Additional file 1:
Tables S9 and S10. In the analyses adjusted for these co-
variates, the estimated effect sizes were similar to those in
the unadjusted analyses (Additional file 1: Table S11). Ef-
fect estimates for the analyses carried out among women
who had never taken HRT were similar to those in the
primary analyses (Additional file 1: Tables S12 and S13).
Discussion
Reliable estimation of the association between uptake and
timing of RRSO and breast cancer risk is critical for
informing counselling and clinical management of BRCA1
and BRCA2 mutation carriers. Our study of 3877 muta-
tion carriers with 426 incident breast cancer cases is the
largest prospective cohort to date and the first prospective
study investigating breast cancer risk after RRSO for
BRCA1 and BRCA2 mutation carriers in the context of
menopausal status.
We found no significant association between RRSO and
breast cancer risk for BRCA1 or BRCA2 mutation carriers,
although the point estimate for the association for BRCA2
mutation carriers was less than 1 (HR = 0.88 (95% CI
0.62–1.24)) and lower when RRSO was carried out before
the age of 45 (HR = 0.68 (95% CI 0.40–1.15) vs 1.07 (95%
CI 0.69–1.64) after age 45). Our overall results are incon-
sistent with previous reports of ~ 50% reduction in breast
cancer risk for BRCA1 mutation carriers [3, 6] but more
consistent with a study by Kotsopolous et al. reporting risk
reduction only for younger BRCA2 mutation carriers [16].
Table 3 Association between RRSO and breast cancer risk
BRCA1 mutation carriers BRCA2 mutation carriers
Person-years BC HR 95% CI Person-years BC HR 95% CI
No RRSO 8353 154a 1.00 – 5769 106b 1.00 –
RRSO at any age (years) 3988 115a 1.23 0.94–1.61 2117 51b 0.88 0.62–1.24
≤ 45 2205 64 1.19 0.88–1.61 964 17 0.68 0.40–1.15
> 45 1783 51 1.34 0.89–2.02 1153 34 1.07 0.69–1.64
Time since RRSO (years)
< 2 1111 40 1.43 1.01–2.03 694 24 1.29 0.82–2.02
2–5 1261 32 1.06 0.71–1.57 722 17 0.82 0.48–1.38
> 5 1616 43 1.18 0.81–1.71 701 10 0.51 0.26–0.99
A Cox regression model was used adjusting for country, stratified by year of birth (≤ 1960, ≥ 1961) and with robust standard errors (clustering by family)
BC breast cancer, RRSO risk-reducing salpingo-oophorectomy, HR hazard ratio
aAmong BRCA1 mutation carriers, tumour pathology was unknown for 5 women without RRSO and 9 following RRSO
bAmong BRCA2 mutation carriers, tumour pathology was unknown for 12 women without RRSO and 7 following RRSO
Mavaddat et al. Breast Cancer Research            (2020) 22:8 Page 5 of 11
The latter study was prospective, but its results were based
on only 3 breast cancers in women aged under 50 years;
our study included more than twice as many BRCA2
mutation carriers overall, and the analyses were based on
31 incident breast cancers in premenopausal BRCA2
mutation carriers. In addition, we investigated associations
by time since RRSO. For BRCA2 mutation carriers, we
observed a decreasing trend in HR with increasing time
since RRSO; relative to women who did not have an
RSSO, the estimated HR > 5 years following RSSO was
0.51. In contrast, for BRCA1 mutation carriers, the HR
was close to 1 at all times since RRSO.
While this is the largest prospective cohort of muta-
tion carriers to date, the number of breast cancer cases
was still limited, and hence, the confidence limits for the
HR estimates were wide. Additional data would be
needed to determine whether or not there is a modest
protective effect of RRSO for BRCA1 mutation carriers
and whether the suggested protective effect in BRCA2
mutation carriers is real.
There was some suggestion of differences in estimated ef-
fect size among studies for BRCA1 mutation carriers in the
< 2-year and ‘2–5-year’ post-RRSO groups (Fig. 1), but the
heterogeneity was not statistically significant. For BRCA2
mutation carriers, there was statistically significant hetero-
geneity in the RRSO > 5 years group (Fig. 2); this appeared
to be driven by a large effect size in GENEPSO, based on
only two breast cancers. Studies differed in methodology
(including frequency of questionnaires, assessment of breast
cancers or RRSO, loss to follow-up, and mean follow-up
time). EMBRACE, GENEPSO, and HEBON ascertained
participants through cancer genetics clinics, while BCFR
used both clinic- and population-based recruitment. There
was also some geographical variation in the uptake and age
at RRSO (Additional file 1: Table S3). However, the cohorts
were recruited and followed up over broadly similar periods
(Additional file 1: Table S2).
The strength of this study is its prospective design. Many
of the biases identified in previous reports were addressed
[7, 9, 17, 18]. We avoided cancer testing-induced bias by
starting follow-up after mutation testing. Women were not
selected for inclusion in the study on the basis of RRSO sta-
tus, and time-dependent covariates were used to examine
the effect of RRSO on breast cancer risk. While it is impos-
sible to rule out bias due to unmeasured confounders in an
observational study, adjustment for potential confounders
Fig. 1 Association between risk-reducing salpingo-oophorectomy and breast cancer risk for BRCA1 mutation carriers in each study centre category
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(family history of breast and ovarian cancer, parity, age at
first birth, and BMI) did not materially influence the results.
In the general population, HRT use is associated with
an increased risk of breast cancer. HRT use after RRSO
may therefore attenuate the risk reduction due to RRSO.
Our preliminary analyses restricted to the subset of
women not reporting HRT use gave broadly similar
results (Additional file 1: Table S13), but the effects of
HRT post-RRSO will need to be further investigated in
larger cohorts and studies that consider the type, formu-
lation, and duration of HRT use.
While often considered the ‘gold standard’ for investigat-
ing exposure-disease associations, prospective cohort stud-
ies are still prone to biases resulting from missing data, loss
to follow-up, and informative censoring. In particular, there
are gaps in data collection between questionnaires and be-
tween the last questionnaire and censoring, during which
risk factors can change. We carried out sensitivity analyses
in which risk factors were scored according to the most
recent questionnaire, thus treating equally women who
reached a particular questionnaire follow-up and those who
dropped out before reaching this time point. This analysis
avoids differential scoring of risk factors between those who
developed breast cancer and those who did not develop
breast cancer but would be expected to result in loss of
power. We also carried out sensitivity analyses excluding
two studies, kConFab and BCFR, as these studies were in-
cluded in a recent analysis of RRSO in women with a family
history of breast cancer (Additional file 1: Table S14) [19].
The results of these analyses were almost identical to those
from the primary analyses. Reporting of natural menopause
is also subject to recall bias and measurement error, and for
about half of women reporting premenopausal status, the
questionnaires did not cover the entire follow-up period.
A potential bias in the estimate of the RRSO association
could arise if the timing of uptake of RRSO was related to
the imminent transition to menopause. If there was a pro-
tective effect of early natural menopause on cancer risk for
mutation carriers, this could result in an overestimation of
the RRSO effect in the overall analysis. However, we found
no evidence for a strong association between age at natural
menopause and breast cancer risk (Additional file 1: Table
S15), so any such bias is likely to be small.
Recent genome-wide association analyses have shown that
age at natural menopause is partially determined by variants
in DNA repair genes, including common coding variants in
BRCA1 [20]. Some studies have suggested that natural
menopause occurs at a younger age for BRCA1 and BRCA2
Fig. 2 Association between risk-reducing salpingo-oophorectomy and breast cancer risk for BRCA2 mutation carriers in each study centre
category. HEBON and, for the 2–5-year category, kConFab were included in the “Other studies” category due to small numbers
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mutation carriers compared with women from the general
population [21–24] and that BRCA1 mutation carriers have
reduced ovarian reserve, and consequently a shortened re-
productive lifespan, compared with non-carriers [25]. BRCA1
mutation carriers have also been found to be more likely to
have occult ovarian insufficiency [21]. The effect of meno-
pause on breast cancer risk might therefore differ in muta-
tion carriers compared with the general population.
It is plausible that oophorectomy may reduce breast
cancer risk in BRCA2 mutation carriers but not in
BRCA1 mutation carriers. Breast cancer incidence peaks
or plateaus at a younger age (early 40s) in BRCA1 than
BRCA2 mutation carriers [2], perhaps suggesting that
much of the carcinogenic process in BRCA1 mutation
carriers takes place before women typically have RRSO
and could influence disease incidence. In addition,
BRCA2-related tumours are mainly oestrogen receptor
(ER)-positive, and BRCA1-related tumours are mainly
ER-negative. Previous analyses have suggested that in
the general population, the association of early menopause
with reduced breast cancer risk is larger for ER-positive
disease [26]. Future analyses stratified by molecular sub-
type of breast cancer should help delineate mechanisms
underlying this difference.
Optimum timing of RRSO should take into account
reported age-specific incidences of ovarian cancer
among BRCA1 and BRCA2 mutation carriers [2]. Na-
tional Comprehensive Cancer Network (NCCN) guide-
lines for example recommend RRSO for BRCA1
mutation carriers, typically between 35 and 40 years of
age and upon completion of child-bearing; for BRCA2
mutation carriers, these guidelines suggest that it is rea-
sonable to delay RRSO until age 40–45 years [27]. Can-
cer Australia clinical guidelines recommend RRSO in
confirmed mutation carriers around age 40 years, while
considering individual risk and circumstances [28]. Ad-
verse effects of RRSO at a young age, including reduced
quality of life, cardiovascular disease, and osteoporosis,
should also be taken into consideration. The results of
our study indicate that caution should be exercised in
conveying information on the risk of breast cancer after
RRSO, and emphasise the need for continued surveil-
lance for breast cancer following RRSO for women who
do not opt for risk-reducing mastectomy,
The results of our analyses further suggest that con-
tinued follow-up of prospective cohorts of mutation
carriers, with linkage to end-point and risk factor
data, are required. These findings need replication in
larger studies of BRCA1 and BRCA2 mutation car-
riers, particularly including more women in whom
RRSO was carried out at a young age. More complete
data on factors such as a family history of breast or
ovarian cancer would be valuable. Prospective studies
with long-term follow-up will also be important for
analysing the association between HRT use and breast
cancer risk following RRSO, as limited data have been
available to date. In addition, RRSO has been reported to
reduce mortality from breast cancer [29–31], and there is
some evidence that breast cancers arising after RRSO are
more indolent than those arising without RRSO [32]. Pro-
spective studies of survival after RRSO would further in-
form counselling and management of BRCA1 and BRCA2
mutation carriers.
Conclusions
While the primary purpose of RRSO is the preven-
tion of ovarian cancer, information on the effect of
RRSO on breast cancer risk is essential for clinical
decision-making, including the decision to undergo a
risk-reducing mastectomy. Our results suggest that a
protective effect of RRSO for BRCA2 mutation car-
riers may manifest five or more years after surgery.
While we cannot rule out an effect of RRSO on
breast cancer risk for BRCA1 mutation carriers, this
effect is unlikely to be as large.
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